Show simple item record

dc.contributor.authorCarnie, Lindsay Een
dc.contributor.authorShah, Dinakshien
dc.contributor.authorVaughan, Kateen
dc.contributor.authorKapacee, Zainul Abedinen
dc.contributor.authorMcCallum, L.en
dc.contributor.authorAbraham, Marcen
dc.contributor.authorBacken, Alison Cen
dc.contributor.authorMcNamara, Mairead Gen
dc.contributor.authorHubner, Richard Aen
dc.contributor.authorBarriuso, Jorgeen
dc.contributor.authorGillespie, Loraineen
dc.contributor.authorLamarca, Angelaen
dc.contributor.authorValle, Juan Wen
dc.date.accessioned2023-06-14T10:28:30Z
dc.date.available2023-06-14T10:28:30Z
dc.date.issued2023en
dc.identifier.citationCarnie LE, Shah D, Vaughan K, Kapacee ZA, McCallum L, Abraham M, et al. Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment-PanDA). Cancers (Basel). 2023 Apr 13;15(8). PubMed PMID: 37190204. Pubmed Central PMCID: PMC10136984. Epub 2023/05/16. eng.en
dc.identifier.pmid37190204en
dc.identifier.doi10.3390/cancers15082277en
dc.identifier.urihttp://hdl.handle.net/10541/626315
dc.description.abstractIntroduction: Pancreatic exocrine insufficiency (PEI) in patients with advanced pancreatic cancer (aPC) is well documented, but there is no consensus regarding optimal screening. Methods and analysis: Patients diagnosed with aPC referred for palliative therapy were prospectively recruited. A full dietetic assessment (including Mid-Upper Arm Circumference (MUAC), handgrip and stair-climb test), nutritional blood panel, faecal elastase (FE-1) and 13C-mixed triglyceride breath tests were performed. Primary objective: prevalence of dietitian-assessed PEI (demographic cohort (De-ch)); design (diagnostic cohort (Di-ch)) and validation (follow-up cohort (Fol-ch)) of a PEI screening tool. Logistic and Cox regressions were used for statistical analysis. Results: Between 1 July 2018 and 30 October 2020, 112 patients were recruited (50 (De-ch), 25 (Di-ch) and 37 (Fol-ch)). Prevalence of PEI (De-ch) was 64.0% (flatus (84.0%), weight loss (84.0%), abdominal discomfort (50.0%) and steatorrhea (48.0%)). The derived PEI screening panel (Di-ch) included FE-1 (normal/missing (0 points); low (1 point)) and MUAC (normal/missing (>percentile 25) (0 points); low (2 points)) and identified patients at high-risk (2-3 total points) of PEI [vs. low-medium risk (0-1 total points)]. When patients from the De-ch and Di-ch were analysed together, those classified by the screening panel as "high-risk" had shorter overall survival (multivariable Hazard Ratio (mHR) 1.86 (95% CI 1.03-3.36); p-value 0.040). The screening panel was tested in the Fol-ch; 78.4% patients classified as "high-risk", of whom 89.6% had dietitian-confirmed PEI. The panel was feasible for use in clinical practice (64.8% patients completed all assessments), with high acceptability (87.5% would repeat it). Most patients (91.3%) recommended dietetic input for all patients with aPC. Conclusions: PEI is present in most patients with aPC; early dietetic input provides a holistic nutritional overview, including, but not limited to, PEI. This proposed screening panel may help to prioritise those at higher risk of PEI, requiring urgent dietitian input. Its prognostic role needs further validation.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.3390/cancers15082277en
dc.titleProspective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic Cancer Dietary Assessment-PanDA)en
dc.typeArticleen
dc.contributor.departmentNutrition & Dietetics, The Christie NHS Foundation Trust, Manchester M20 4BX, UKen
dc.identifier.journalCancersen
dc.description.noteen]
refterms.dateFOA2023-06-14T11:57:38Z


Files in this item

Thumbnail
Name:
37190204.pdf
Size:
1.191Mb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record